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Abstract
A prospective (2005–2007) hospital-based multicentre surveillance of EORTC/MSG-proven or probable invasive aspergillosis (IA) cases
whatever the underlying diseases was implemented in 12 French academic hospitals. Admissions per hospital and transplantation proce-
dures were obtained. Cox regression models were used to determine risk factors associated with the 12-week overall mortality. With
424 case-patients included, the median incidence/hospital was 0.271/103 admissions (range 0.072–0.910) without signiﬁcant alteration of
incidence and seasonality over time. Among the 393 adults (62% men, 56 years (16–84 years)), 15% had proven IA, 78% haematological
conditions, and 92.9% had lung involvement. Acute leukaemia (34.6%) and allogeneic stem cell transplantation (21.4%) were major host
factors, together with chronic lymphoproliferative disorders (21.6%), which emerged as a new high-risk group. The other risk host fac-
tors consisted of solid organ transplantation (8.7%), solid tumours (4.3%), systemic inﬂammatory diseases (4.6%) and chronic respiratory
diseases (2.3%). Serum galactomannan tests were more often positive (‡69%) for acute leukaemia and allogeneic stem cell transplanta-
tion than for the others (<42%; p <10)3). When positive (n = 245), cultures mainly yielded Aspergillus fumigatus (79.7%). First-line anti-
fungal therapy consisted of voriconazole, caspofungin, lipid formulations of amphotericin, or any combination therapy (52%, 14%,
8% and 19.9%, respectively). Twelve-week overall mortality was 44.8% (95% CI, 39.8–50.0); it was 41% when ﬁrst-line therapy included
voriconazole and 60% otherwise (p <0.001). Independent factors for 12-week mortality were older age, positivity for both culture and
galactomannan and central nervous system or pleural involvement, while any strategy containing voriconazole was protective.
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Introduction
Invasive aspergillosis (IA) remains the main cause of morbidity
and mortality in patients undergoing allogeneic haematological
stem cell transplantation (HSCT), but characteristics of these
patients and those with myeloma [1], solid tumours [2] and
solid-organ transplant (SOT) [3,4], and management of their
diseases, are changing [5]. Additionally, increased numbers of
cases due to underlying bronchial damage [6] and/or associ-
ated with intensive care [7,8], and fewer cases related to
advanced stages of HIV infection, are now reported [9].
Therefore, the proﬁle of patients considered at risk of IA con-
tinues to expand while the outcome seems to improve.
Trying to describe the epidemiology of IA is challenging as
the diagnosis requires standardized criteria [10,11]. To over-
come the limitations of setting speciﬁc [12] or single hospital
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[2] studies, we implemented a dedicated network to pro-
spectively collect all cases of IA. Our aim was to describe its
incidence per hospital whatever the underlying diseases, its
potential variations according to centres and transplant pro-
cedures, and to assess the contribution of diagnostic tools,
the ﬁrst-line antifungals used and the prognostic factors.
Patients and Methods
Data collection
A prospective surveillance programme (SAIF for ‘Surveillance
des Aspergilloses Invasives en France’) was implemented in
three regions (Paris-Ile de France, Grand Ouest and Rhoˆne-
Alpes) by the National Reference Centre for Mycoses and
Antifungals (NRCMA, Institut Pasteur) with the participation
of 12 acute care teaching hospitals and the French National
Public Health Surveillance Institute (Institut de Veille Sani-
taire). All new IA episodes were recorded whatever the age
and the underlying disease by each local microbiologist,
which limited the risk of missing cases because at least one
microbiological criterion was compulsory for validation [10].
Each case was notiﬁed through a secured website using a
standardized questionnaire and analysed by a local commit-
tee. To maintain adhesion to the network, the coordination
committee organized semestrial meetings with participating
microbiologists. Demographics, underlying conditions, diag-
nostic tools, dates of hospitalization, ﬁrst-line antifungal ther-
apy and outcome at day 90 were recorded. The study was
approved by the Institut Pasteur Institutional Review Board.
The diagnostic investigations and therapeutic management
followed local practices. Only proven and probable IA
according to 2002 European Organization for Research and
Treatment of Cancer and Mycoses Study Group criteria
were considered [10]. The date of the ﬁrst radiological or
microbiological criteria was considered as the date of IA
diagnosis. Dissemination was deﬁned as more than two non-
contiguous organs involved. The threshold of positivity for
the galactomannan (GM) index (Platelia Aspergillus; Biorad,
Marnes-la-Coquette, France) in serum was 1 for 2005
according to the manufacturer’s recommendations at that
time, and 0.5 thereafter. Missing information and ambiguous
answers were checked by the database manager with the
corresponding microbiologist and each case was validated by
three of us.
As invasive aspergillosis was managed in the referral cen-
tre where the patient was followed for his immunosuppres-
sive condition, at least in the case of haematological
malignancy or transplant procedure, we decided to use
patient admissions per hospital as well as numbers of HSCT
and SOT recipients in participating hospitals as denominators
obtained through national health statistics http://www.pla-
tines.sante.gouv.fr/.
Statistical analysis
Means and standard deviations (SDs) are shown when dis-
tributions were conﬁrmed normal while median and IQR
are used otherwise. We compared baseline characteristics
of groups by use of the v2 test or Fisher’s exact test for
categorical variables, and the t-test for continuous variables
after Bonferonni adjustment at p <0.001. Other compari-
sons were exploratory analysis and we did not check the
p-value.
Overall survival at 12 months was measured from the
date of diagnosis to the last follow-up or death from any
cause. For the multivariate analysis, hazard ratios and their
95% conﬁdence intervals (95% CIs) were determined by
means of the Cox regression model with shared frailty to
determine factors associated with time to death. Frailties
that are random effects are entered on the hazard function
to model correlation within each hospital. The proportional
hazard assumption was tested using weighted residuals. Clini-
cally relevant variables with p-value <0.25 were removed fol-
lowing a backwards-stepwise selection procedure, leaving
only variables with p-value <0.05 in the ﬁnal model. Interac-
tion terms were explored to take into account potential
baseline hazards of death by hospital. Overall survival (cumu-
lative survival probability and 95% CI) was estimated by the
Kaplan–Meier method and comparisons of survival were per-
formed by logrank tests.
The analysis took into account only cases for which the
corresponding parameter was available. All variables were
coded and analysed with Stata computer package version 10
(Stata Statistical Software; Stata Corporation, College Sta-
tion, TX, USA).
Results
Incidence
From January 2005 to December 2007, 424 case-patients
were recorded. Overall, the median incidence of IA was
0.271 per 1000 admissions (range 0.072–0.910). No signiﬁ-
cant change in the incidence was observed over time and no
seasonal trend was noted. The overall incidence was 8.1%
(84/1043) and 0.9% (18/2010) in allogeneic and autologous
HSCT patients, respectively. Among SOT patients, the calcu-
lated IA incidence was 4.8% (7/146), 4.1% (7/172), 0.8% (9/
1067) and 0.3% (11/3157) for heart, lungs, liver and kidney
transplantation, respectively.
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Description of the population
Out of the 424 case-patients, 31 were children (i.e.
<18 years). The subsequent analyses concerned only the 393
adults (62% male patients; median age = 56 years; range, 18–
84 years). Cases were classiﬁed as proven (n = 60, 15%) and
probable (n = 333, 85%) IA. Overall, 305 (77.6%) patients
had haematological malignancies. The main underlying risk
factors/diseases were divided into eight groups (Table 1)
after dispatching the patients with autologous HSCT (n = 19)
and the HIV-positive patients (n = 8) according to their asso-
ciated underlying disease. The major one was acute leukae-
mia (AL) (n = 136, 34.6%). Chronic lymphoproliferative
disorders emerged as the second haematological underlying
disease (n = 85, 21.6%), followed by allogeneic HSCT
(n = 84, 21.4%). All patients with chronic lymphoproliferative
disorders accounted for 35% (n = 106) of all haematological
malignancies. Other patients had SOT (n = 34, 8.7%), solid
tumours (n = 17, 4.3%), systemic inﬂammatory diseases with
high-dose steroid therapy (n = 18, 4.6%), or chronic respira-
tory diseases (n = 9, 2.3%). Finally, ten (2.5%) patients had
none of the above risk factors, including ﬁve with IA diag-
nosed at autopsy without known risk factor.
Main characteristics of invasive aspergillosis
For patients with AL, IA occurred for 68% (93/136) of them
during the induction phase of chemotherapy, for 27% during
consolidation and for 5% during palliative care. For the 85
non-allografted patients with chronic lymphoproliferative dis-
orders, IA occurred for 27% (23/85) during the induction
phase, for 67% (57/85) during malignancy relapse/non-
control, and for 6% (5/85) during palliative care. The time
interval between allogeneic HSCT and the occurrence of IA
was <40 days, ‡40–100< and ‡100 days for 16 (19%), 11
(13%) and 57 (68%) patients, respectively. IA occurred in the
ﬁrst 12 weeks following heart transplantation (6/7) and at
least 100 days after surgery for the other transplant proce-
dures (18/27).
Localization of IA was mostly pulmonary (365/393, 92.9%),
either isolated (324/393, 82%) or associated with other local-
izations (41/393, 10%) that consisted mainly of sinus (n = 18)
and central nervous system (CNS, n = 20) involvement. Iso-
lated extrapulmonary aspergillosis was documented in 28
patients (8%) and consisted of sinusitis (n = 11) and/or CNS
localizations (n = 9).
Diagnostic tools and microbiological results
Imaging. Chest computed tomography (CT) scan was per-
formed in 310 (78.9%) patients, with no signiﬁcant difference
according to underlying diseases. Chest nodules were found
in 252/310 (81.3%) patients with pulmonary IA, associated
with halo sign or cavitation in 47 (15.2%) and 126 patients
(40.6%), respectively. There were 58 (18%) patients with
proven or probable IA, with CT signs not reported as nod-
ule, halo sign and/or cavitation, without a statistically signiﬁ-
cant difference according to the eight groups (Table 2).
GM serum detection. GM serum detection was performed at
least twice for 345/393 (88%) patients. Despite a change in
the positivity’s threshold in 2006, no modiﬁcation in the per-
centage of cases with two positive tests was noted over time
(p 0.7). Two positive tests were recorded in 197/345
patients (57%), with variations ranging from 69% in AL and
allogeneic HSCT to 40%, 26% and 0% in the chronic lympho-
proliferative disorders, SOT and the chronic respiratory dis-
ease groups, respectively (p <104). GM detection was
performed in 91 BAL ﬂuids and was reported positive for 43
of them (47%). GM positivity in BAL ﬂuid (index ‡ 1.5) was
the only microbiological criterion in four patients (Table 2).
Microbiological investigations. Direct examination and culture
of clinical specimens were performed in 325 (82.7%) patients.
Direct examination was positive in 56% (182/325), with the
TABLE 1. Risk factors for invasive aspergillosis and underly-
ing diseases of the 393 adult patients of the study
Risks factors/underlying diseases n (%)
Acute leukaemia 136/393 (34.6)
Acute myeloid leukaemia 90/136 (66.2)
Acute lymphoid leukaemia 21/136 (15.4)
Myelodysplasia 9 (6.6)
Acute transformation 16 (11.8)
Allogeneic HSCT 84/393 (21.4)
Acute myeloid leukaemia 28 (33.3)
Acute lymphoid leukaemia 18 (21.4)
Myelodysplasia 4 (4.8)
Acute transformation 7 (8.3)
Lymphoma 13 (15.5)
Chronic lymphoid leukaemia 3 (3.6)
Multiple myeloma 5 (6.0)
Aplasia 3 (3.6)
Others 3 (3.6)
Chronic lymphoproliferative disorders 85/393 (21.6)
Lymphoma 42 (49.4)
Chronic lymphoid leukaemia 26 (30.6)
Multiple myeloma 13 (15.3)
Others 4 (4.7)
Solid organ transplantation 34/393 (8.7)
Heart 7 (20.1)
Lung 7 (20.1)
Liver 9 (26.5)
Kidney 11 (32.4)
Solid tumours 17/393 (4.3)
Broncho-pulmonary and others 6 (35.3)
Others 11 (64.7)
Systemic inﬂammatory diseases 18/393 (4.6)
Vasculitis 5 (27.8)
Inﬂammatory rheumatism 3 (16.7)
Glomerulonephritis 2 (11.1)
Others 8 (44.4)
Chronic respiratory diseases 9/393 (2.3)
Chronic obstructive pulmonary disease 2 (22.2)
Pulmonary ﬁbrosis 4 (44.4)
Asthma 2 (22.2)
Others 1 (11.1)
None of the above risk factors 10/393 (2.5)
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lowest rate in the allogeneic HSCT group (p 0.005). Culture
was positive for 76% (246/325) (from 53% (50/95) for AL to
>88% for the other groups (p <10)3)). When positive
(n = 246), cultures yielded 196 A. fumigatus (79.7%), 11
A. niger, 10 A. ﬂavus, seven A. nidulans, ﬁve A. terreus, ﬁve
other species and 12 mixtures all including A. fumigatus. No
non-fumigatus species was reported in non-haematological
patients (Table 2).
Treatment
First-line therapy prescribed for at least 48 h was reported
for 367 (93.4%) patients. For 26 patients, there was no pre-
scription of antifungal therapy (autopsy ﬁndings, death before
ﬁnal diagnosis, palliative care). Monotherapy was prescribed
for 294 (80%) patients while any combination was used in 73
(19.9%), with no signiﬁcant difference according to the
underlying group (Table 2).
Outcome
The outcome at day 90 was available for 388/393 (99%)
patients, with death recorded in 174 patients (44.8%; 95%
CI, 39.8–50.0) (Table 3). Univariate analysis identiﬁed several
parameters associated with death. Thus, the proportion of
older patients, those with positive culture and at least two
GM positive serum samples (35.8% vs. 19.3%) and those with
CNS involvement (10.9% vs. 4.7%) or pleural effusion (41.7%
vs. 18.0%) was higher, while the proportion of patients
receiving voriconazole either alone or in combination (54.3%
vs. 75.8%) or the proportion of patients with pulmonary
nodules, halo sign and/or cavitation (59.2% vs. 78.5%) was
smaller when comparing the patients who died with those
who survived (Table 3 and Fig. 1a,b).
In the multivariate analysis, after taking into account the
within-hospital correlation, the parameters independently
associated with an increased risk of death were an older age,
a diagnosis based on positive culture together with two posi-
tive GM detections in serum samples, the presence of pleural
TABLE 3. Parameters associated with deaths within 90 days after the diagnosis of IA for the 388/393 adult patients for whom
the outcome was available
Parameters
Univariate analysis Multivariate analysis
No. deaths
(n = 214)
Deaths
before day
90 (n = 174) p OR (95% CI) p
Gender male 135/214 (63.1%) 106/174 (60.9%) 0.675
Median age (IC 95%) 52.5 (50.5–54.5) 55.7 (53.5–58.0) 0.034 1.02 (1.00–1.03) 0.034
Underlying risk factors
Acute leukaemia 84 (38.3%) 51 (29.3%) 0.018
Allogeneic graft 37 (17.3%) 47 (27.0%)
Lymphoid disorders 48 (22.4%) 35 (20.1%)
Solid organ transplantation 24 (11.2%) 10 (5.8%)
Solid tumours 5 (2.3%) 10 (5.8%)
Systemic 8 (3.7%) 10 (5.8%)
Chronic respiratory 5 (2.3%) 4 (2.3%)
Others 3 (1.4%) 7 (4.0%)
Positive culture and positive
galactomannan on ‡2 serum samples
29/150 (19.3%) 39/109 (35.8%) 0.004 1.72 (1.07–2.74) 0.023
Central nervous system involvement 10/214 (4.7%) 19/174 (10.9%) 2.01 (1.04–3.90) 0.039
Pleural effusion 34/189 (18.0%) 55/132 (41.7%) <10)3 2.38 (1.53–3.70) <10)3
Presence of nodule, halo sign and/or cavitation 155/197 (78.7%) 97/164 (59.2%) <10)3
Initial antifungal treatment including voriconazole 150/198 (75.8%) 89/164 (54.3%) <10)3 0.53 (0.34–0.82) 0.005
FIG. 1.Overall survival at 3 months after diagnosis of invasive
aspergillosis. (a) Patients diagnosed either with one (plain line) or
with at least two mycological (dashed line) criteria. (b) Patients given
any antifungal regimens containing voriconazole, either alone (plain
line) or in combination (dotted line), or any antifungal regimens with-
out voriconazole (dashed line).
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effusion or CNS involvement, while an initial antifungal treat-
ment including voriconazole (alone or in combination) was
associated with a decreased risk of death (Table 3).
Discussion
The incidence of IA was 0.271/1000 admissions, from 0.072
to 0.91 according to the hospital, without any signiﬁcant
temporal trend or any seasonal inﬂuence. The different
recruitment of the participating hospitals and obvious differ-
ences in clinical approaches to IA diagnosis, which will be
further analysed, may explain these differences.
As expected, haematological malignancies provided the
highest proportion of IA. Surprisingly, 35% of haematological-
associated IA occurred in patients with chronic lymphoprolif-
erative disorders, with 67% occurring during second-line
therapies. Studies focused on this population could support
our results, which suggest an intensifying treatment or the
cumulative immune suppression as a possible cause of
increased risk of IA in this speciﬁc group [1]. When consid-
ering the subpopulations, the incidence was 8.1% among allo-
geneic HSCT recipients, which is within the range of
previous reports [13–15]. Of note, 70% occurred >100 days
after the graft, as underlined by others [12,13] although not
always reported [14]. For autologous HSCT, the 0.9% inci-
dence is concordant with other data [12,14,16].
The incidence of IA according to the transplant procedure
was in the range previously recorded [4], with a late occur-
rence after lungs, liver or kidney transplantation. HIV infec-
tion dramatically decreased (2%) compared with previous
reports [16,17]. IA was recorded in non-haematology cancer
patients, systemic inﬂammatory or chronic respiratory dis-
eases and some other conditions in up to 15% of the popula-
tion, higher than previously reported [16,17]. In these latter
patients, we evidenced the low yield of serum GM detection.
GM contribution depends on the likelihood of IA occurrence
[18] and on previous antifungal therapy [19]. Another plausi-
ble explanation would be the pathophysiology of IA in deeply
neutropenic patients vs. patients receiving prolonged steroid
therapy [20]. Indeed, lymphoproliferative diseases corre-
spond to patients for whom neutropenia is not the predomi-
nant risk factor [21]. The poor performance of serum GM in
non-neutropenic patients and the difﬁculty in fulﬁlling the
clear-cut CT-scan criteria in intensive care unit patients [11]
underline the need for reﬁning diagnostic criteria for these
populations [6]. This underlines also the interest of the main
mycological criterion of the present study, which remains a
positive culture [22]. Also of note was the high rate (56%) of
positive direct examination.
Twelve-week overall mortality was 44.8%, with differences
between groups, similar to a report of 48.8% in a single-cen-
tre study [2]. For AL, the present mortality rate was 37.8%,
a ﬁgure close to the 33% recently reported [23]. For alloge-
neic HSCT recipients, our 56% overall mortality is close to
the 57.5% rate in the TRANSNET study [24] but by far
higher than the 35.5% reported in the PATH Alliance regis-
try [12]. Nevertheless, the mortality rate is lower than the
66% previously observed, suggesting a substantial improve-
ment of IA prognosis in the allogeneic HSCT recipients [25].
In SOT patients, the mortality rate found here is concordant
with the TRANSNET study (29.4% and 34.4%, respectively)
[24].
Independent factors associated with death were here an
older age, the combination of two positive GM tests and a
positive microbiological investigation, and the involvement of
pleura and/or CNS. If involvement of pleura or CNS has pre-
viously been identiﬁed as a prognostic factor [2,25,26], it is
not the case for the combination of the biological diagnostic
tools. This could be explained by a more advanced disease
with a larger fungal burden. This emphasizes the importance
of individualizing patients with unique or multiple positive
tests in future clinical trials. In contrast, CT-scan signs sug-
gestive of pulmonary IA were associated with a better prog-
nosis, which was potentially ascribed to an earlier diagnosis
[27].
Voriconazole represented the main ﬁrst-line therapy pre-
scription (51.8% of cases) while amphotericin B deoxycholate
has almost disappeared. Caspofungin and antifungal combina-
tions represented 14% and 17% of the ﬁrst-line therapy pre-
scriptions, with an increase or decrease in use over time,
respectively. Of note, combination therapy was reported in
47.2% of HSCT patients [12] despite lack of beneﬁt in this
population [24] and lack of recommendation [28].
Interestingly, although not obtained during a randomized
trial but taking into account variations in relation to the hos-
pital, the use of any strategy using voriconazole was an inde-
pendent factor for survival. The 90-day survival rates were
59% and 40% in voriconazole-treated and non-treated
patients, respectively. These data are reminiscent of those
reported in the pivotal voriconazole trial (70.8% and 57.9%
in the voriconazole and amphotericin B groups, respectively)
[29].
In conclusion, this prospective multicentre surveillance
study allowed us to demonstrate that IA incidence markedly
varied according to clinical centres. An emergence of IA in
patients with heavily treated chronic lymphoproliferative dis-
orders was recorded. Among the other major issues, the
poor contribution of serum GM in all non-haematology
groups, the need to better assess fungal burden by combining
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fungal culture and serum antigen detection and the role of
voriconazole as ﬁrst-line therapy are emphasized.
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